Notice of Results

Summary by AI BETAClose X

Oxford BioDynamics Plc has announced that it expects to release its results for the year ended 30 September 2025 on Tuesday, 16 December 2025. The company, which specializes in precision clinical diagnostics using its EpiSwitch® 3D genomics platform, currently offers two commercial products: the EpiSwitch® PSE for prostate cancer screening and the EpiSwitch® CiRT for predicting response to immuno-oncology treatments.

Disclaimer*

UK 100

Latest directors dealings